false
0001862150
0001862150
2026-11-13
2026-11-13
0001862150
CING:CommonStockParValue0.0001PerShareMember
2026-11-13
2026-11-13
0001862150
CING:WarrantsExercisableForCommonStockMember
2026-11-13
2026-11-13
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
November
13, 2026
CINGULATE
INC.
(Exact
name of registrant as specified in its charter)
| Delaware |
|
001-40874 |
|
86-3825535 |
(State
or other jurisdiction of
incorporation) |
|
(Commission
File
Number) |
|
(IRS
Employer
Identification
No.) |
1901
W. 47th Place
Kansas
City, KS 66205
(Address
of principal executive offices) (Zip Code)
(913)
942-2300
(Registrant’s
telephone number, including area code)
___________________________________________________________________
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
| ☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol(s) |
|
Name
of exchange on which registered |
| Common
Stock, par value $0.0001 per share |
|
CING |
|
The
Nasdaq Stock Market LLC
(Nasdaq
Capital Market) |
| Warrants,
exercisable for common stock |
|
CINGW |
|
The
Nasdaq Stock Market LLC
(Nasdaq
Capital Market) |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405)
or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 1.01 Entry into Material Definitive Agreement
As previously disclosed, on March 24, 2026,
Cingulate Inc. (the “Company”) entered into an ATM Sales Agreement, or the ATM Agreement, with A.G.P./Alliance Global Partners
(“A.G.P.”) as sales agent (the “Agent”), pursuant to which the Company may offer and sell, our common stock,
par value $0.0001 per share, or common stock, having an aggregate offering price of up to $100,000,000, from time to time, through the
Agent.
On November 13, 2026, the Company entered
into Amendment No. 2 to the ATM Agreement (the “Amendment”) with A.G.P. and Maxim Group LLC (“Maxim”) solely
to add Maxim Group LLC as an Agent under the ATM Agreement. The foregoing description of the Amendment is qualified in its entirety by
reference to the full text of the Amendment, which is filed as Exhibit 10.1 hereto.
Item
2.02. Results of Operations and Financial Condition.
On
November 13, 2026, Cingulate Inc. issued a press release announcing its financial results for the quarter ended September 30, 2026 and
providing a regulatory update. A copy of the press release is furnished as Exhibit 99.1 and incorporated by reference. The information
in this Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities
of that Section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended,
or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits
| Exhibit
No. |
|
Description |
| |
|
|
| 10.1 |
|
Amendment No. 1 to ATM Agreement, by and among the Company, A.G.P. and Maxim, dated November 13, 2026 |
| |
|
|
| 99.1 |
|
Press Release dated November 13, 2026 |
| |
|
|
| 104 |
|
Cover
Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| |
CINGULATE
INC. |
| |
|
|
| Dated:
November 13, 2026 |
By: |
/s/
Jennifer L. Callahan |
| |
Name: |
Jennifer
L. Callahan |
| |
Title: |
Chief
Financial Officer |
Exhibit
99.1
Cingulate
Inc. Reports Third Quarter 2026 Financial Results and Provides Regulatory Update on CTx-1301 NDA Resubmission
Manufacturing
Work Addressing FDA CMC Information Requests Substantially Completed
NDA
Resubmission Expected Between December 2026 and January 2027
KANSAS
CITY, Kan., Nov. 13, 2026 — Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed
Release™ (PTR™) drug delivery platform to develop a pipeline of next-generation products, today reported financial results
for the quarter ended September 30, 2026, and announced that it has substantially completed the manufacturing work required to address
the U.S. Food and Drug Administration’s (FDA) chemistry, manufacturing and controls (CMC) information requests for CTx-1301. The
Company expects to resubmit the new drug application (NDA) for CTx-1301 between December 2026 and January 2027.
“With
the manufacturing work substantially complete, we are now finalizing the data and documentation needed to resubmit the NDA for CTx-1301,
and we expect to do so by January 2027, potentially sooner,” stated Cingulate Chairman and CEO Shane J. Schaffer. “Importantly,
the FDA’s Complete Response Letter did not raise any concerns about the clinical safety or efficacy of CTx-1301. We thank our shareholders
for their patience and continued support as we work to bring this treatment to patients with ADHD.”
Regulatory
Update: CTx-1301 NDA Resubmission Progress
On
June 1, 2026, the FDA issued a Complete Response Letter (CRL) for the CTx-1301 (dexmethylphenidate HCl) NDA. The CRL identified specific
requests for additional CMC information and did not identify any concerns regarding the clinical safety or efficacy of CTx-1301, the
Company’s lead ADHD asset.
Since
then, Cingulate and its contract development and manufacturing organization (CDMO), Bend Bioscience, have substantially completed the
manufacturing work required to address the CMC requests in the CRL and are finalizing the supporting data and documentation for resubmission.
As announced on November 9, 2026, the Company expects to resubmit the NDA between December 2026 and January 2027. After the FDA receives
the resubmission, it is expected to classify it as a Class 1 or Class 2 resubmission, which carry review goals of two and six months,
respectively.
Third
Quarter Financial Results
Cash
and Working Capital: As of September 30, 2026, Cingulate had approximately $23.2 million in cash and cash equivalents, compared to
$11.0 million as of December 31, 2025. The increase was primarily driven by capital raised during the first nine months of 2026, including
the close of a $12.0 million private placement in the first quarter and $22.5 million of capital raised on Cingulate’s At-the-Market
Agreement with AGP and Purchase Agreement with Lincoln Park Capital, partially offset by $20.4 million in cash used for operations. As
of September 30, 2026, Cingulate had approximately $18.8 million in working capital, an increase of $16.1 million as compared to December
31, 2025.
Under
its current business plan, the Company believes its cash and cash equivalents will be sufficient to fund operations into mid-2027, including
costs associated with seeking regulatory approval for CTx-1301, and continuing the build-out of commercial readiness capabilities.
R&D
Expenses: Research and development expenses were $2.9 million for the three months ended September 30, 2026, an increase of 2.2%
from $2.8 million for the three months ended September 30, 2025, driven primarily by higher drug manufacturing costs to address the CMC
information requested in the FDA’s CRL, partially offset by lower clinical operations costs following the conclusion of clinical
study activities in early 2025, the absence of regulatory costs incurred in the prior-year period in connection with preparing the CTx-1301
NDA, and lower personnel expenses. For the nine months ended September 30, 2026, R&D expenses were $6.6 million, a decrease of 15.3%
from $7.8 million for the nine months ended September 30, 2025, driven primarily by lower clinical operations and regulatory costs, partially
offset by increased manufacturing activities related to CTx-1301 following the CRL.
SG&A
Expenses: Selling, general and administrative expenses (SG&A) were $4.6 million for the three months ended September 30,
2026, compared to $3.1 million for the three months ended September 30, 2025, an increase of 45.5%. For the nine months ended September
30, 2026, SG&A expenses were $14.2 million, compared to $6.6 million for the nine months ended September 30, 2025, an increase of
116.6%. The increases were driven primarily by the build-out of commercial readiness capabilities, including increased headcount and
expanded market access, pricing, reimbursement and medical affairs activity conducted through Indegene, the Company’s commercialization
partner.
Net
Loss: Net loss was $7.7 million for the three months ended September 30, 2026, compared to $7.3 million for the three months ended
September 30, 2025. For the nine months ended September 30, 2026, net loss was $22.9 million, compared to $16.2 million for the nine
months ended September 30, 2025. The increases primarily reflect the higher SG&A expenses described above, partially offset in the
third quarter by a smaller loss from the change in fair value of derivative and lower interest expense, and for the nine-month period
by lower R&D expenses.
Cingulate Inc.
Consolidated Balance Sheet Data
| | |
September 30, | | |
December 31, | |
| | |
2026 | | |
2025 | |
| Cash and cash equivalents | |
$ | 23,185,900 | | |
$ | 10,953,383 | |
| Total assets | |
$ | 28,150,677 | | |
$ | 15,073,263 | |
| Total liabilities | |
$ | 7,383,547 | | |
$ | 12,564,356 | |
| Working Capital | |
$ | 18,832,234 | | |
$ | 1,695,633 | |
| Accumulated deficit | |
$ | (155,288,781 | ) | |
$ | (132,375,031 | ) |
| Total stockholders’ equity | |
$ | 20,767,130 | | |
$ | 2,508,907 | |
Cingulate Inc.
Consolidated Statements of Operations
| | |
Three Months Ended September 30, | | |
Nine Months Ended September 30, | |
| | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| Operating expenses: | |
| | | |
| | | |
| | | |
| | |
| Research and development | |
$ | 2,910,660 | | |
$ | 2,848,544 | | |
$ | 6,581,803 | | |
$ | 7,772,109 | |
| Selling, general and administrative | |
| 4,580,358 | | |
| 3,147,291 | | |
| 14,247,412 | | |
| 6,579,735 | |
| Operating loss | |
| (7,491,018 | ) | |
| (5,995,835 | ) | |
| (20,829,215 | ) | |
| (14,351,844 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Change in fair value of derivative | |
| (69,323 | ) | |
| (772,169 | ) | |
| (1,235,366 | ) | |
| (1,016,682 | ) |
| Interest and other income (expense), net | |
| (171,056 | ) | |
| (573,058 | ) | |
| (849,169 | ) | |
| (808,475 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Loss before income taxes | |
| (7,731,397 | ) | |
| (7,341,062 | ) | |
| (22,913,750 | ) | |
| (16,177,001 | ) |
| Income tax benefit (expense) | |
| - | | |
| - | | |
| - | | |
| - | |
| | |
| | | |
| | | |
| | | |
| | |
| Net loss | |
| (7,731,397 | ) | |
| (7,341,062 | ) | |
| (22,913,750 | ) | |
| (16,177,001 | ) |
About
Attention Deficit/Hyperactivity Disorder (ADHD)
ADHD
is a chronic neurobiological and developmental disorder that affects millions of children and often continues into adulthood. The estimated
market size of the US ADHD market is approximately 100 million annual prescriptions. The condition is marked by an ongoing pattern of
inattention and/or hyperactivity-impulsivity that interferes with functioning or development. In the U.S., over 20 million patients have
been diagnosed with ADHD. Among this group, 12 million are adults and over 8 million are under the age of 17. According to the CDC, just
53.6 percent of all children and teens with ADHD reported they were actively treating their symptoms with medication in 2022, with 65-90
percent demonstrating clinical ADHD symptoms that persist into adulthood. Current market trends demonstrate that adult ADHD prevalence
is larger and growing faster than the child and adolescent segments combined.
About
CTx-1301
CTx-1301
(dexmethylphenidate HCl) is a once-daily, multi-core tablet utilizing Cingulate’s proprietary Precision Timed Release™ (PTR™)
platform to deliver three precisely timed releases of active medication across the day. This design aims to provide rapid onset of effect
and entire active-day duration. CTx-1301 is being evaluated for the treatment of ADHD under the FDA’s 505(b)(2) pathway. In October
2025, the FDA accepted for review the NDA for CTx-1301 and assigned a PDUFA target action date of May 31, 2026. On June 1, 2026, the
FDA issued a Complete Response Letter for the CTx-1301 NDA; the Company and its CDMO have since substantially completed the manufacturing
work required to address the CMC requests, and the Company expects to resubmit the NDA between December 2026 and January 2026. There
can be no assurance regarding the timing of any resubmission or whether approval will occur.
About
Precision Timed Release™ (PTR™) Platform Technology
Cingulate
is developing ADHD and anxiety disorder product candidates capable of achieving true once-daily dosing using Cingulate’s innovative
PTR drug delivery platform technology. It incorporates a proprietary Erosion Barrier Layer (EBL) providing control of drug release at
precise, pre-defined times with no release of drug prior to the intended release. The EBL technology is enrobed around a drug-containing
core to give a tablet-in-tablet dose form. It is designed to erode at a controlled rate until eventually the drug is released from the
core tablet. The EBL formulation, Oralogik™, is licensed from BDD Pharma. Cingulate intends to utilize its PTR technology to expand
and augment its clinical-stage pipeline by identifying and developing additional product candidates in other therapeutic areas in addition
to Anxiety and ADHD.
About
Cingulate Inc.
Cingulate
Inc. (NASDAQ: CING) is a biopharmaceutical company utilizing its proprietary PTR drug delivery platform technology to build and advance
a pipeline of next-generation pharmaceutical products, designed to improve the lives of patients suffering from frequently diagnosed
conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. With an initial focus on the treatment
of ADHD, Cingulate is identifying and evaluating additional therapeutic areas where PTR technology may be employed to develop future
product candidates, including to treat anxiety disorders. Cingulate is headquartered in Kansas City. For more information, visit Cingulate.com.
Forward-Looking
Statements
This
press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include all statements, other than
statements of historical fact, regarding our current views and assumptions with respect to future events regarding our business, including
statements with respect to our plans, assumptions, expectations, beliefs and objectives with respect to product development, clinical
studies, clinical and regulatory timelines, the timing and outcome of any resubmission of the CTx-1301 NDA, market opportunity, competitive
position, business strategies, potential growth opportunities, our expected cash runway, and anticipated capital needs and financing
plans. These statements are generally identified by the use of such words as “may,” “could,” “should,”
“would,” “believe,” “anticipate,” “forecast,” “estimate,” “expect,”
“intend,” “plan,” “continue,” “outlook,” “will,” “potential”
and similar statements of a future or forward-looking nature. Readers are cautioned that any forward-looking information provided by
us or on our behalf is not a guarantee of future performance. Actual results may differ materially from those contained in these forward-looking
statements as a result of various factors disclosed in our filings with the Securities and Exchange Commission (SEC), including the “Risk
Factors” section of our Annual Report on Form 10-K filed with the SEC on March 18, 2026 and our Quarterly Report on Form 10-Q for
the period ended June 30, 2026, and our other filings with the SEC. All forward-looking statements speak only as of the date on which
they are made, and we undertake no duty to update or revise any forward-looking statements, whether as a result of new information, future
events or otherwise, except to the extent required by law.
Investor
& Media Relations:
Thomas
Dalton
Vice
President, Corporate and Government Relations, Cingulate
tdalton@cingulate.com
(480)
529-5434